Generic Locoid Availability

See also: Generic Locoid Lipocream

Locoid is a brand name of hydrocortisone topical, approved by the FDA in the following formulation(s):

LOCOID (hydrocortisone butyrate - cream;topical)

  • Manufacturer: PRECISION DERMAT
    Approval date: March 31, 1982
    Strength(s): 0.1% [RLD] [AB]

LOCOID (hydrocortisone butyrate - lotion;topical)

  • Manufacturer: PRECISION DERMAT
    Approval date: May 18, 2007
    Strength(s): 0.1% [RLD]

LOCOID (hydrocortisone butyrate - ointment;topical)

  • Manufacturer: PRECISION DERMAT
    Approval date: October 29, 1982
    Strength(s): 0.1% [RLD] [AB]

LOCOID (hydrocortisone butyrate - solution;topical)

  • Manufacturer: PRECISION DERMAT
    Approval date: February 25, 1987
    Strength(s): 0.1% [RLD] [AT]

Has a generic version of Locoid been approved?

A generic version of Locoid has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Locoid and have been approved by the FDA:

hydrocortisone butyrate cream;topical

  • Manufacturer: GLENMARK GENERICS
    Approval date: September 27, 2013
    Strength(s): 0.1% [AB]
  • Manufacturer: TARO PHARM INDS
    Approval date: August 3, 2005
    Strength(s): 0.1% [AB]

hydrocortisone butyrate ointment;topical

  • Manufacturer: TARO
    Approval date: December 27, 2004
    Strength(s): 0.1% [AB]

hydrocortisone butyrate solution;topical

  • Manufacturer: TARO PHARM INDS
    Approval date: January 14, 2004
    Strength(s): 0.1% [AT]

Note: No generic formulation of the following product is available.

  • hydrocortisone butyrate - lotion;topical

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Locoid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Stabilized steroid composition and method for its preparation
    Patent 7,378,405
    Issued: May 27, 2008
    Inventor(s): Patel; Pravin M.
    Assignee(s): Triax Pharmaceuticals, LLC
    Stabilized 17-substituted hydrocortisone containing compositions and methods of manufacture. Isomerization of the hydrocortisone component of topical steroid compositions is markedly reduced by introducing an omega-6. acid in the form of linoleic acid into the skin preparation. Preferably, the linoleic acid is added as a component of refined safflower oil. The omega-6 acid has been found to be an effective way of preventing the isomerization of hydrocortisone 17-butyrate into the undesirable isomer HC21-B.
    Patent expiration dates:
    • December 19, 2026
      ✓ 
      Drug product
  • Stabilized steroid composition and method for its preparation
    Patent 7,981,877
    Issued: July 19, 2011
    Inventor(s): Patel; Pravin M.
    Stabilized, 17-substituted hydrocortisone containing compositions and methods of manufacture are disclosed. Isomerization of the hydrocortisone component of topical steroid compositions is markedly reduced by including an omega-6 acid component in the form of a free acid or as a compound such as an ester. Specifically disclosed are methods for preventing the isomerization of hydrocortisone 17-butyrate into hydrocortisone 21-butyrate through the use of safflower oil.
    Patent expiration dates:
    • January 23, 2025
      ✓ 
      Drug product

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
ATTopical products. There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of in vivo bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded AT. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded AB when supported by adequate bioequivalence data, and BT in the absence of such data.
Hide
(web5)